BFEC
ITCI

Benjamin F. Edwards & Company’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Benjamin F. Edwards & Company’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-84
Closed -$6K – 2259
2024
Q1 		$6K Sell
84
-12
-13% -$825 ﹤0.01% 1839
2023
Q4 		$7K Buy
+96
New +$5.52K ﹤0.01% 1788

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Benjamin F. Edwards & Company's ITCI Position: Q2 2024 in Review

Benjamin F. Edwards & Company sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2024, closing a stake of 84 shares — an estimated $6K sold.

Benjamin F. Edwards & Company first reported a position in ITCI in Q4 2023 and held it in 2 quarters. The position peaked at $7K in Q4 2023. 375 funds tracked by Wall St. Rank hold ITCI as of Q2 2024.

  • Benjamin F. Edwards & Company reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2024 after selling out during the quarter.
  • Benjamin F. Edwards & Company sold 84 Intra-Cellular Therapies Inc. shares in Q2 2024, an estimated $6K.
  • Benjamin F. Edwards & Company first reported a position in Intra-Cellular Therapies Inc. in Q4 2023 and held it in 2 quarters.
  • Benjamin F. Edwards & Company's Intra-Cellular Therapies Inc. position peaked at $7K in Q4 2023.
  • 375 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2024.

Based on Benjamin F. Edwards & Company's 13F filing for Q2 2024, filed 12 Aug 2024.